Navigation Links
Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting
Date:12/8/2008

9 percent for placebo) and also for median increase in percentage of seizure-free days (7.4 percent, 9.3 percent, and 12.1 percent vs. 5.4 percent for placebo) for those entering the maintenance period.

The pooled results among all patients in the intent-to-treat analysis, including those who dropped out during the titration period, also demonstrated statistically significant reductions in seizure frequency at all doses studied compared to placebo:

-- Seizure frequency was reduced by 33.3 percent for the 200 mg/day group, 36.8 percent for the 400 mg/day group, and by 39.4 percent for the 600 mg/day group, compared with 18.4 percent for placebo (p<.05 for the 200 mg/day group and p<.0001 for the 400 and 600 mg/day groups vs. placebo).

-- Responder rates were 34.1 percent for 200 mg/day, 39.7 percent for 400 mg/day, and 39.6 percent for 600 mg/day, compared with 22.6 percent for placebo (p<.05 for the 200 mg/day group and p<.0001 for the 400 and 600 mg/day groups vs. placebo).

Poster Session 3, December 8, 2008, 8:00 - 9:00 am (Poster 3.196)

Steve Chung, MD, David Rudd, David Hebert, PhD, Pamela Doty

Barrow Neurological Institute, Phoenix, AZ; SCHWARZ BIOSCIENCES (a member of the UCB Group), Research Triangle Park, Raleigh, North Carolina

Lacosamide Efficacy is Independent of Concomitant AED(s) Treatment

This analysis evaluated pooled data from the placebo and 400 mg/day Vimpat(R) treatment groups of each trial by the most frequently used concomitant AEDs. The most commonly used concomitant AEDs for this patient population were carbamazepine, lamotrigine, levetiracetam, valproate, and oxcarbazepine.

Overall, reduction in seizure frequency was 36.8 percent for adjunctive treatment with Vimpat(R) 400 mg/day versus 18.4 percent for adjunctive treatment with placebo. When analyzed by individual concomitant AED use, Vimpa
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
2. Derma Sciences Announces Multiple Clinical Posters Featuring MEDIHONEY(R) and ALGICELL Ag(R) to be Presented at Upcoming Wound Care Conference
3. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
4. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
5. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
6. Environmental Tectonics Corporation Announces a Multiple Sale of Hyperbaric Monoplace Chambers to Comprehensive Healthcare Solutions
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
10. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
11. Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... 2014 An analysis by Replikins, Ltd. of ... Mers CoV virus strains has revealed extensive conservation ... This conservation and sharing of specific Replikin gene structures ... candidate, as it did for the H5N1 influenza vaccine ... have been found to be effective (1,2). ...
(Date:8/26/2014)... , August 26, 2014 , ... hospitals with surgery validation using its Stratasys Objet24 and Objet30 ... surgery on 3D printed models prior to operations reduces theatre ... effective aid for both patient and surgeon   ... a global leader of 3D printing and additive manufacturing solutions, ...
(Date:8/26/2014)... AVENTURA. Fla. , Aug. 26, 2014 /PRNewswire/ ... trades under the symbol (NUUU) has two (2) ... Inc. Our two subsidiaries harness scientifically advanced technology ... NUUU,s Renuell Int,l, Inc. ... breakthrough anti-aging skin care products that is made ...
(Date:8/26/2014)... , Aug. 26, 2014 Trovagene, Inc. ... Generation Dx Summit; Moving Assays to the Clinic ... and Monitoring of Cell Free Tumor DNA in ... component of its Precision Cancer Monitoring (PCM) platform ... sensitivity for the detection of tumor DNA mutations ...
Breaking Biology Technology:Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 2Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 3Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 5Technology Applications International Corporation, Trading Symbol NUUU now trading on NASDAQ's Over the Counter Bulletin Board (OTC BB) 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 3Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 4
... TELK ) announced that its 2008 second quarter ... 11, 2008 at 4:30 p.m. Eastern time,(1:30 p.m. Pacific ... financial results for the second quarter ended June 30, ... Telik,s website at, http://www.telik.com or by telephone at ...
... Aug. 4 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group ... Bio-Tech Products (Shandong) Co., Ltd. (Kiwa Shandong),has ... China Organic Food,Certification Center (COFCC)., After ... appraisal of,Kiwa Shandong,s products, the China Organic ...
... Share Proposal is Best and Final Offer, INDIANAPOLIS, ... ) today reaffirmed that its $3.00 per share purchase ... its best and final offer,for the San Diego-based biotechnology ... signing of a definitive merger agreement, whereby,Lilly will acquire ...
Cached Biology Technology:Kiwa Bio-Tech Receives Nationally Recognized Organic Products Certification 2Kiwa Bio-Tech Receives Nationally Recognized Organic Products Certification 3Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals 2Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals 3
(Date:8/26/2014)... increased risk of autism among children of women ... the known increased risk associated with severe maternal ... publication in Molecular Psychiatry , investigators from ... a diagnosis of autism spectrum disorder was more ... during pregnancy than in those with no prenatal ...
(Date:8/25/2014)... has experienced widespread adoption of robot-assisted prostate removal ... The BJU International study also found ... traditional surgeries, their costs are decreasing over time. ... in operations to remove the prostate. To examine ... prostatectomy (RARP) procedures for prostate cancer patients, Steven ...
(Date:8/25/2014)... Diego School of Medicine have found one of the ... a deadly brain cancer are resistant to drug therapy. ... tumor, but in its epigenetic signature. These findings have been ... Oncotarget . , "There is a growing interest to ... cell," said Clark Chen, MD, PhD, vice-chairman of Research and ...
Breaking Biology News(10 mins):Study calls into question link between prenatal antidepressant exposure and autism risk 2Study calls into question link between prenatal antidepressant exposure and autism risk 3US has seen widespread adoption of robot-assisted cancer surgery to remove the prostate 2Finding keys to glioblastoma therapeutic resistance 2
... at the Texas A&M Health Science Center Institute ... Edinburgh have uncovered how a bacterial pathogen interacts ... methicillin-resistant Staphylococcus aureus (MRSA) infections, a ... the potentially deadly disease. Their work appears ...
... the wrong times, the results can be genetic disaster. ... in fruit flies that yank chromosomes, the DNA-carrying structures, ... condensin II, separate chromosomes by twisting them into supercoils ... Scientists had known of condensin II but did ...
... ON A new and insidious environmental threat ... researchers from Queen,s and York universities. Along ... team has documented biological damage caused by declining ... Calling the phenomenon "aquatic osteoporosis," Queen,s PhD ...
Cached Biology News:Keeping chromosomes from cuddling up 2Keeping chromosomes from cuddling up 3Queen's University biologists find new environmental threat in North American lakes 2
Acetylcholinesterase from human and monkey....
...
... Dye runs faster than Bromophenol blue,or ... gels.,Orange G dye migrates with DNA ... migration at this size,prevents the obscuring ... the front of DNA migration.,The Orange ...
... Gel loading solution, ... for non-denaturing polyacrylamide and ... nucleic acids and offers ... tracking dyes (bromphenol blue ...
Biology Products: